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Available online 26 February 2014ReferencesIn an otherwise excellent review of drug related complications in
cystic fibrosis (CF), Peckham and Whittaker briefly comment on
complications related to pancreatic enzyme replacement therapy
(PERT). They state correctly that high dose pancreatic enzyme
supplementationwas linkedwith cases of colonopathy both here and
in the US but go on to describe the role of Methyl Acrylic Acid
Co-polymer (used as an enteric coating, Eudragit) in the aetiology of
colonopathy. This, however, has not been established.
In 1996, the now discredited pathologist van Velzen carried out a
series of exploratory studies in adolescent pigs. After 7 days caecal
gavage of of Eudragit L 30 D55 in doses ranging from 10 to
500 mg/kg/day, changes were noted at all dose levels in 7 out of 9
animals, but they did not closely resemble those seen in the human
cases of fibrosing colonopathy in patients with CF. These findings
were not observed in animals gavaged with the monomer
components of the co-polymer [1]. These studies were industry
funded, and as yet uncorroborated. Indeed, attempts to confirm these
findings in rats failed to produce intestinal change with enzyme or
co-polymer alone in normal control animals, but did produce
intestinal eosinophilia and necrosis of the jejuno-ileo muscle layer,
together with inflammatory change in the liver when enzymes alone
(without co-polymer) were given in high dosage in animals
pretreated with agents that increased intestinal permeability (oleic
acid and reserpine) to mimic CF intestinal physiology [2].
As certain slow-release 5ASA used in the treatment of inflam-
matory bowel disease also contain a Eudragit L-based coating,
Peckham and Whittaker go on to cite a case report by Prieto et al.,
(2009) [3], of a 10 year-old boy with inflammatory bowel disease
treated with mesalazine (Claversal, Faes Farma, Spain), who
developed colonopathy-like changes. However, previous attemptshttp://dx.doi.org/10.1016/j.jcf.2014.02.001
1569-1993/© 2014 European Cystic Fibrosis Society. Published by Elsevier B.V. Ato establish a link between Eudragit L containing 5ASA
preparations and fibrosing colonopathy have been unsuccessful
[4]. Moreover, other conditions have been associated with
fibrosising colonopathy including an adult patient without cystic
fibrosis who received treatment with pancreatic enzymes for a
pancreato-duodenectomy and newborns with meconium ileus due
to cystic fibrosis who had never received pancreatic enzymes. Cases
have also been reported in patients receiving low-dose PERT [5].
Whatever the role of the co-polymer, colonopathy can occur
with all forms of PERT if given in excess [6]. We should continue
to observe the advice of the MCA/CSM/FDA that PERT doses
should not exceed a maximum of 10,000 units of lipase/kg/day [7]
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